Altitude
What the 2026 Midterms Mean for Psychedelics: Who Won, Who Lost, and Which Compounds Feel It
Policy

What the 2026 Midterms Mean for Psychedelics: Who Won, Who Lost, and Which Compounds Feel It

Democrats took both chambers of Congress. Texas threw out the two statewide officials who built its $50 million ibogaine trial. And Congress's psychedelics caucus came through with both co-chairs intact.

Nathan Richardson • Nov 4, 2026

A race-by-race look at the 2026 midterm results that touch psychedelics — the Senate and House flips, the FDA's new overseers, the Texas ibogaine program's changed leadership, new governors in New Mexico, Colorado and California, and the two ballot measures that actually mentioned drugs.

Photo: Unsplash

Psychedelics weren't on many ballots on Tuesday. The first statewide psilocybin measure since 2018 never qualified, and Alaska's backers have pushed theirs to 2028. Even so, the results reshuffled most of the people who control the money, oversight and state programs this industry runs on. Networks project Democrats will take the House and the Senate. In Texas, the governor and lieutenant governor who launched the country's biggest state-funded ibogaine trial both lost.

The chart covers everyone whose result touches a specific compound or program. Results are unofficial until certified, and a few House calls are still projections.

Scorecard of 2026 midterm races affecting psychedelics, color-coded red for Republicans and blue for Democrats, listing each candidate's office, result, and the compound or program at stake

The FDA Gets New Overseers

Congress doesn't approve drugs. The FDA's reviewers will decide Usona's psilocybin NDA and the rest of the pipeline on our trials tracker, whoever chairs what. What Congress controls is oversight hearings, appropriations and must-pass bills like the defense authorization, and on all three the gavels are about to change hands.

The biggest change came before Tuesday. Sen. Bill Cassidy (R-LA) chairs the Senate HELP Committee, which oversees the FDA and HHS. He lost his Louisiana primary in May after clashing with HHS Secretary Robert F. Kennedy Jr., finishing third, per CNN. Now that Democrats control the Senate, the HELP gavel moves across the aisle in January. That puts Kennedy and FDA leadership in front of a committee with every incentive to question the agency's fast-track approach to psychedelics. That includes the National Priority Vouchers and the April executive order directing the FDA and DEA to speed up psychedelic trials.

Sen. Susan Collins (R-ME) chairs the Senate Appropriations Committee. She conceded to Democrat Troy Jackson, who was leading 53.7% to 46.3% in NBC's count. The Appropriations chair has a lot of say over VA and Pentagon research budgets, which is where most federal psychedelic trial money sits. In Texas, Democrat James Talarico beat Attorney General Ken Paxton for an open Senate seat. Talarico has said he'd work to federally legalize marijuana. We couldn't find anything he's said on psychedelics.

There's a timing wrinkle. The current Republican Congress keeps working until January. In July the House passed its FY2027 defense bill with two psychedelics amendments led by Rep. Morgan Luttrell (R-TX). One extends the Pentagon's psilocybin, MDMA, ibogaine and 5-MeO-DMT research program to 2033. The other writes the April executive order into law. The Senate hadn't acted on either as of late August. Whether they survive the lame-duck negotiations is the nearest real test.

The House Caucus Survived. Its Loudest Republicans Didn't.

Both co-chairs of the Congressional PATH Caucus, the bipartisan group behind most federal psychedelic research bills, won reelection. Rep. Jack Bergman (R-MI) beat Callie Barr again, 53% to 45% in unofficial returns, and Rep. Lou Correa (D-CA) is projected to win with about two-thirds of the vote. Two Democratic co-sponsors of the caucus's VA psychedelic research centers bill also held on. Rep. Susie Lee (D-NV), the closest race on our watch list going in, won by about 20 points. Rep. Sarah Elfreth (D-MD) took 65% in Maryland's official count.

The losses on the Republican side happened mostly before November. Rep. Dan Crenshaw (R-TX), who wrote the original DoD psychedelic research grant program with Luttrell, lost his March primary to state Rep. Steve Toth. Luttrell, who has talked openly about his own ibogaine treatment (we profiled him in our People Series), is retiring. Rep. Nancy Mace (R-SC) gave up her seat for a governor's race and lost that primary in June. Her Breakthrough Therapies Act, co-led with Sens. Cory Booker and Rand Paul, would have made rescheduling easier for MDMA and psilocybin once they got breakthrough status. It now needs a new House lead.

That leaves the GOP's veterans-and-psychedelics wing a lot thinner just as Democrats take over the committees. Bergman becomes its most senior voice.

State by State

Texas: the ibogaine trial loses its champions. Gov. Greg Abbott signed SB 2308 in 2025, creating a $50 million state ibogaine research program. When no drug company submitted a qualifying proposal, Lt. Gov. Dan Patrick and House Speaker Dustin Burrows promised in March that the state would fully fund the work itself. UTMB Health and UTHealth Houston now lead the multicenter trial. On Tuesday Democrat Gina Hinojosa unseated Abbott, and Democrat Vikki Goodwin beat Patrick. Hinojosa has backed medical marijuana and decriminalization in the Texas House, per NORML. We found no public statement from her or Goodwin on ibogaine. The money is already awarded, so the open question is whether the 2027 legislature keeps funding the trial without the two people who championed it.

New Mexico: psilocybin gets a governor who's on record. Deb Haaland won by about 14 points. During the campaign she told the Santa Fe Reporter she supports the state's Medical Psilocybin Act and more research into psilocybin for substance use disorder and depression. The program has to launch by the end of 2027, and the state health department has been trying to move faster.

Colorado: a new governor for the natural medicine program. Attorney General Phil Weiser won the race to replace the term-limited Jared Polis. Polis was the most visible governor in the country on psychedelics, and Colorado is in its second year of licensed psilocybin healing centers. We couldn't find a stated position from Weiser on the program, which makes this the state to watch.

Arizona: Gov. Katie Hobbs won reelection over Andy Biggs. That keeps the governor's office the same while the state's $5 million Barrow Neurological Institute ibogaine trial gets started. It's a 40-person placebo-controlled study in traumatic brain injury.

California: Former HHS Secretary Xavier Becerra beat Steve Hilton. Gavin Newsom vetoed the state's 2023 psychedelics decriminalization bill, so Becerra will be the one who signs or vetoes the next attempt. His record on the issue is thin.

Idaho and Oregon: the only drug questions on the ballot. Idaho voters rejected HJR 4 by roughly two to one. The amendment would have given only the legislature the power to legalize any drug or psychoactive substance, closing the citizen-initiative route for psilocybin as well as cannabis. Redmond, Oregon voted a third time to keep licensed psilocybin service centers out of city limits, 57% to 43% in late-night returns.

What to Watch

Three things will show whether any of this matters. First, whether the defense bill's psychedelics amendments make it through the lame duck. Second, who takes over the HELP Committee in January and whether one of the first FDA oversight hearings asks about psychedelic fast-tracking. Third, whether Texas's 2027 budget still funds the ibogaine trial. We'll keep the trials tracker and our company intelligence pages updated as the answers come in, and our scored 2026 legislative session is the baseline for the state fights ahead.

This article is for educational and informational purposes only and is not medical or legal advice. Ibogaine, psilocybin and MDMA remain Schedule I under federal law, and ibogaine carries known cardiac risks.

Sources

← Back to Journal